# US 2025/0367265 A1 · Pharmaceutical parenteral composition of dual glp1/2 agonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367265 A1
- Document ID: US20250367265A1
- Status: Published application
- Kind: A1
- Application number: 19/236,746
- Filed: 2025-06-12
- Published: 2025-12-04
- Earliest claimed: 2019-06-14
- Assignees: Zealand Pharma A/S
- Applicants: Zealand Pharma A/S
- Inventors: Lise Giehm; Alistair Vincent Gordon Edwards
- Web page: https://patentgrep.com/patent/US20250367265A1

## CPC

- A61K 9/0029: {Parenteral nutrition; Parenteral nutrition compositions as drug carriers}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/26: Glucagons
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- C07K 14/001: {by chemical synthesis}
- C07K 14/605: Glucagons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects. In particular, the present invention relates to isotonic pharmaceutical compositions for parenteral administration.

## Claims

### Claim 1

An isotonic parenteral pharmaceutical composition, comprising:
a. at least about 1 mg/mL of one or more GLP-1/GLP-2 dual agonist wherein the one or more GLP-1/GLP-2 dual agonist is Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD-OH (CPD1OH) (SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof:
b. about 1 mM to about 200 mM of buffer component; and
c. about 1 mM to about 500 mM of one or more tonicity agent,
wherein said one or more tonicity agent comprises or a non-ionic tonicity agent, wherein the non-ionic tonicity agent is mannitol
wherein said composition further comprises a solvent, and
wherein said composition has a pH of about pH 6.0 to about pH 8.2.

### Claim 2 (depends on 1)

The isotonic parenteral pharmaceutical composition of claim 1 wherein said non-ionic tonicity agent is D-mannitol.

### Claim at position 3

3-6. (canceled)

### Claim 7 (depends on 1)

The isotonic parenteral pharmaceutical composition according to claim 1, wherein said buffer component is selected from the group consisting of phosphate buffer, citrate buffer, histidine buffer, tris buffer or bis tris, or a combination thereof.

### Claim 8 (depends on 1)

The isotonic parenteral pharmaceutical composition according to claim 1, wherein said buffer component is phosphate buffer.

### Claim 9 (depends on 1)

The isotonic parenteral pharmaceutical composition of claim 1, wherein said buffer component is a sodium phosphate buffer.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The isotonic parenteral pharmaceutical composition according to claim 1, wherein said buffer component is at a final concentration of about 15 mM to about 200 mM.

### Claim 12 (depends on 11)

The isotonic parenteral pharmaceutical composition according to claim 11 wherein said buffer component is at a final concentration of about 20 mM.

### Claim 13 (depends on 1)

The isotonic parenteral pharmaceutical composition according to claim 1, wherein said mannitol is at a final concentration of about 190 mM to about 240 mM.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The isotonic parenteral pharmaceutical composition of claim 1, wherein the osmolality of the composition is about 230 mOsmol/kg to about 370 mOsmol/kg.

### Claim at position 13

16-19. (canceled)

### Claim 20 (depends on 1)

The isotonic parenteral pharmaceutical composition of claim 1, wherein said one or more GLP-1/GLP-2 dual agonist is present at a concentration of about 1 mg/mL to about 15 mg/mL.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The isotonic parenteral pharmaceutical composition of claim 1, comprising a phosphate buffer at a concentration of about 15 mM to about 30 mM, mannitol at a concentration of about 230 mM, water for injection and sodium hydroxide and/or hydrochloric acid for pH adjustment to a pH of about pH 8.0, wherein said one or more GLP-1/GLP-2 dual agonist is CPD1OH or a chloride salt thereof present at about 10 mg/mL.

### Claim at position 17

23-29. (canceled)

### Claim 30 (depends on 1)

The isotonic parenteral pharmaceutical composition of claim 1, which is suitable for s.c. or i.v. injection into human subjects.

### Claim 31 (depends on 1)

The isotonic parenteral pharmaceutical composition of claim 1, wherein said composition has a shelf-life of at least about 1 month.

### Claim 32 (depends on 1)

The isotonic parenteral pharmaceutical composition of claim 1, wherein said composition has a chemical stability of at least about 90% after 12 months storage.

### Claim at position 21

33-36. (canceled)

### Claim 37 (depends on 1)

A method of:
(i) increasing intestinal mass, improving intestinal function, increasing intestinal blood flow, or repairing intestinal damage or dysfunction, in a subject in need thereof; or
(ii) prophylaxis or treatment of malabsorption, ulcers, short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease, irritable bowel syndrome, pouchitis, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, mucositis induced by chemotherapy or radiation therapy, diarrhoea induced by chemotherapy or radiation therapy, low grade inflammation, metabolic endotoxemia, necrotising enterocolitis, primary biliary cirrhosis, hepatitis, fatty liver disease, or gastrointestinal side-effects of inflammatory conditions, in a subject in need thereof; or
(iii) reducing or inhibiting weight gain, reducing gastric emptying or intestinal transit, reducing food intake, reducing appetite, or promoting weight loss, in a subject in need thereof; or
(iv) prophylaxis or treatment of obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnoea, inadequate glucose control, glucose tolerance, dyslipidaemia, diabetes, pre-diabetes, metabolic syndrome or hypertension, in a subject in need thereof;
wherein the method comprises administering to the subject the isotonic parenteral pharmaceutical composition of claim 1.

### Claim 38 (depends on 1)

The isotonic parenteral pharmaceutical composition according to claim 1, wherein the composition comprises about 50 mM to about 450 mM of one or more tonicity agent.

### Claim 39 (depends on 39)

The isotonic parenteral pharmaceutical composition according to claim 39, wherein the composition has a pH of about pH 7.0 to about pH 8.0.

### Claim 40 (depends on 1)

The isotonic parenteral pharmaceutical composition according to claim 1, wherein the composition has a pH of about pH 8.0.

### Claim 41 (depends on 11)

The isotonic parenteral pharmaceutical composition according to claim 11, wherein said buffer component is at a final concentration of about 15 mM to about 30 mM.

### Claim 42 (depends on 1)

The isotonic parenteral pharmaceutical composition according to claim 1, wherein said non-ionic tonicity agent is mannitol at a final concentration of about 230 mM.
